Humoral response to the influenza a H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients

Clinical Infectious Diseases

Volumn 52, Issue 2, 2011, Pages 248-256

  Manuel, Oriol ^a   Pascual, Manuel ^a   Hoschler, Katja ^b   Giulieri, Stefano ^a   Alves, Deolinda ^a   Ellefsen, Kim ^a   Bart, Pierre Alexandre ^a   Venetz, Jean Pierre ^a   Calandra, Thierry ^a   Cavassini, Matthias ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN; HEMAGGLUTININ; INFLUENZA VACCINE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PREDNISONE; PROTEINASE INHIBITOR; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DRUG FEVER; DRUG SAFETY; FATIGUE; FEMALE; GEOMETRY; HEMAGGLUTINATION INHIBITION; HEMAGGLUTINATION INHIBITION ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNOASSAY; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; INFLUENZA A (H1N1); INFLUENZA VIRUS A; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; MICRONEUTRALIZATION ASSAY; ORGAN TRANSPLANTATION; PANDEMIC; PRIORITY JOURNAL; SEROCONVERSION; STUDY DESIGN; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADULT; ALPHA-TOCOPHEROL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DRUG COMBINATIONS; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HIV INFECTIONS; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOCOMPROMISED HOST; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; ORGAN TRANSPLANTATION; POLYSORBATES; SQUALENE; VACCINATION;

EID: 79951841213     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciq104     Document Type: Article

References (27)

1. Swine influenza A (H1N1) infection in two children-Southern California. Morb Mortal Wkly Rep. March-April 2009;58:400-402.
2. Zimmer SM, Burke DS. Historical perspective-Emergence of influenza A (H1N1) viruses. N Engl J Med 2009;361:279-285.
3. Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010;362:1708-1719.
4. Jamieson DJ, Honein MA, Rasmussen SA, et al. Novel Influenza A (H1N1) Pregnancy Working Group. H1N1 2009 influenza virus infection during pregnancy in the USA. Lancet 2009;374:451-458.
5. Lister P, Reynolds F, Parslow R, et al. Swine-origin influenza virus H1N1, seasonal influenza virus, and critical illness in children. Lancet 2009;374:605-607.
6. Kumar D, Michaels MG, Morris MI, et al. On behalf of the American Society of Transplantation H1N1 Collaborative Study Group. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis 2010;10:521-526.
7. Kumar D, Morris MI, Kotton CN, et al. AST Infectious Diseases Community of Practice Transplant Infectious Diseases Section of TTS. Guidance on novel influenza A/H1N1 in solid organ transplant recipients. Am J Transplant 2010;10:18-25.
8. Strategic Advisory Group of Experts on Immunization-report of the extraordinary meeting on the influenza A (H1N1) 009 pandemic, 7 July 2009. Wkly Epidemiol Rec 2009;84:301-308.
9. Clark TW, Pareek M, Hoschler K, et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009;361:2424-2435.
10. Greenberg ME, Lai MH, Hartel GF, et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009;361:2405-2413.
11. Zhu FC, Wang H, Fang HH, et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009;361:2414-2423.
12. Waddington CS, Walker WT, Oeser C, et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 2010;340: c2649.
13. Liang XF, Wang HQ, Wang JZ, et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, doubleblind, randomised, placebo-controlled trial. Lancet 2010;375:56-66.
14. Carmona A, Omeñaca F, Tejedor JC, et al. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months. Vaccine 2010;28:5837-5844.
15. Bickel M, Wieters I, Khaykin P, et al. Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. AIDS 2010;24: F31-F35.
16. Ellis JS, Zambon MC. Molecular investigation of an outbreak of influenza in the United Kingdom. Eur J Epidemiol 1997;13:369-372. (Pubitemid 27306182)
17. Danziger-Isakov L, Cherkassky L, Siegel H, et al. Effects of influenza immunization on humoral and cellular alloreactivity in humans. Transplantation 2010;89:838-844.
18. Paschke R, Pollok M, Geiger H, et al. Increased immunogenicity with an MF59-adjuvanted influenza vaccine compared to a conventional sub-unit vaccine in renal transplant recipients. J Prev Med Hyg. 2003;44:79-84.
19. Magnani G, Falchetti E, Pollini G, et al. Safety and efficacy of two types of influenza vaccination in heart transplant recipients: a prospective randomised controlled study. J Heart Lung Transplant 2005;24:588-592. (Pubitemid 40693882)
20. Candon S, Thervet E, Lebon P, et al. Humoral and cellular immune responses after influenza vaccination in kidney transplant recipients. Am J Transplant. 2009;9:2346-2354.
21. Manuel O, Humar A, Chen MH, et al. Immunogenicity and safety of an intradermal boosting strategy for vaccination against influenza in lung transplant recipients. Am J Transplant. 2007;7:2567-2572. (Pubitemid 47561624)
22. Hancock K, Veguilla V, Lu X, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009;361:1945-1952.
23. Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, Zambon M. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet 2010;375:1100-1108.
24. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972;70:767-777.
25. Roman F, Vaman T, Kafeja F, Hanon E, Van Damme P. AS03 (A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. Clin Infect Dis. 2010;51:668-677.
26. Vajo Z, Tamas F, Sinka L, Jankovics I. Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial. Lancet 2010;375:49-55.
27. Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 2009;9:493-504.